Milosevich Gregory M sold $484K of DHR

Milosevich Gregory M (Executive Vice President) sold 2,100 shares of DANAHER CORP /DE/ (DHR) at $230.62 ($0.48M total) on 2026-11-09.

Original reporting
SEC EDGAR · Milosevich Gregory M
Published Nov 10, 2026, 10:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 10:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$DHR
Bearish
medium confidence
Mentioned
$DHR
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DHRBearishLow
01

Why it matters

A modest insider sell may prompt short‑term price dip, but the size is too small to drive major moves.

02

Market read

Small insider sale with limited market impact; useful for short‑term monitoring.

03

What to watch

Potential upcoming corporate actions or compensation plans not disclosed.

Relevance 4/10Novelty 4/10Timing: post-market filing

Background

Form 4 filings disclose insider transactions and are used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$DHRBearishMedium confidence
Context

Executive Vice President Gregory M. Milosevich sold 2,100 Danaher shares for $484,302 at $230.62 each.

Expected impact

likely modest downward pressure as the market prices the insider sell.

Evidence & confidence

A 2,100‑share sale represents a small portion of holdings and is under $1M, so impact is limited but may signal caution.

Market effects

Minimal effect on the health‑care equipment sector.

No significant regional impact.

Limited to Danaher investors.

Counterpoint

The sale could be routine portfolio rebalancing and not indicative of negative fundamentals.

Key entities

  • Gregory M. Milosevich

    Executive Vice President of Danaher Corp.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$DHRMed

Beckman Coulter receives FDA clearance for bacterial infection test

Beckman Coulter Diagnostics, part of Danaher Corporation, received FDA clearance for the Access MeMed BV assay, a blood test distinguishing bacterial from viral infections in patients aged 90 days and older. The test runs on the company's DxI 9000 and Access 2 immunoassay analyzers, providing results in 15 minutes. Developed with MeMed, the test measures immune-response proteins to generate a bacterial infection likelihood score.

$DHRMed

UBS reiterates Danaher stock Buy rating on Q3 results and outlook

UBS reiterated a Buy rating on Danaher (DHR) with a $260 price target, citing Q3 results and outlook. The stock, near its 52-week high, has risen 27.6% in six months. Danaher reported Q3 core revenue growth of 2.5% to 3.0% and adjusted earnings of $2.11 per share, exceeding expectations. Stifel also raised its price target to $260, noting strong nonrespiratory growth.